When we think of injectables, we tend to picture treatments and fixes for common complaints like crow’s feet, laugh lines and even chin and jawline insecurities, but usage for injectables is constantly expanding. You may have heard of people getting Botox for migraines or other such treatments, but a recent FDA-approval has just given permission for the neuromodulator Daxxify to treat a painful neck condition.
What Daxxify’s new FDA-approval means for those with cervical dystonia
Revance Therapeutics’ Daxxify has gained popularity in recent years when it comes to anti-wrinkle injectables, but the FDA just approved the neuromodulator for use as a treatment for a painful neck condition called cervical dystonia, which involves an involuntary contraction of the muscles in the neck that causes the head to tort to one side.
The FDA-approval allows Daxxify to enter the $2.5 billion dollar therapeutic neuromodulator market—one that accounts for treatments that act directly on the nerves—and cervical dystonia accounts for a whopping $345 million dollars of that market, making Daxxify’s entry into the realm for cervical dystonia treatment huge for the company.
A wider launch for this treatment is set for 2024, but for now, Revance is moving into a preview phase for this Daxxify treatment alongside doctors and key opinion leaders, and pricing information will become available upon the launch. In terms of clinical results thus far, FDA data reveals that patients with cervical dystonia saw the effects of different dosages of Daxxify treatment last from 20 to 24 weeks, as opposed to three months with other neuromodulators.
